Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities

Leukemia Research

Volumn 31, Issue 11, 2007, Pages 1589-1592

  Pawarode, Attaphol ^a   Sait, Sheila N J ^a   Nganga, Alain ^a   Coignet, Lionel J ^a   Barcos, Maurice ^a   Baer, Maria R ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia; Chronic myeloid leukemia; Cytogenetics; Imatinib mesylate

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DRUG DOSE INCREASE; GENE SEQUENCE; HUMAN; HUMAN CELL; KARYOTYPE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DNA PRIMERS; DNA, COMPLEMENTARY; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; PIPERAZINES; PYRIMIDINES;

EID: 35448980782     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.01.022     Document Type: Article

References (24)

1. O'Brien S.G., Guilhot F., Larson R.A., et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
2. Terre C., Eclache V., Rousselot P., et al. France Intergroupe pour la Leucemie Myeloide Chronique. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 18 (2004) 1340-1346
3. Kovitz C., Kantarjian H., Garcia-Manero G., Abruzzo L.V., and Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108 (2006) 2811-2813
4. Fiskus W., Pranpat M., Balasis M., et al. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 12 (2006) 5869-5878
5. Huntly B.J., Bench A., and Green A.R. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 102 (2003) 1160-1168
6. Chu S., Xu H., Shah N.P., Snyder D.S., Forman S.J., Sawyers C.L., et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105 (2005) 2093-2098
7. Vardiman J.W., Imbert M., Pierre R., Brunning R.D., Thiele J., and Flandrin G. Chronic myelogenous leukaemia. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World Health Organization classification of tumours: pathology and genetics of tumours of hematopietic and lymphoid tissues (2001), IARC Press, Lyon, France 20-26
8. Morimoto A., Ogami A., Chiyonobu T., et al. Early blastic transformation following complete cytogenetic response in a pediatric chronic myeloid leukemia patient treated with imatinib mesylate. J Pediatr Hematol Oncol 26 (2004) 320-322
9. Jabbour E., Kantarjian H., O'Brien S., et al. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 107 (2006) 480-482
10. Alimena G., Breccia M., Latagliata R., et al. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. Cancer 107 (2006) 1008-1013
11. Huntly B.J., Reid A.G., Bench A.J., et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98 (2001) 1732-1738
12. Quintas-Cardama A., Kantarjian H., Talpaz M., et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105 (2005) 2281-2286
13. Alimena G., Breccia M., Mancini M., et al. Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome. Leukemia 18 (2004) 361-362
14. Guilbert-Douet N., Morel F., Le Bris M.J., et al. Clonal chromosomal abnormalities in the Philadelphia chromosome negative cells of chronic myeloid leukemia patients treated with imatinib. Leukemia 18 (2004) 1140-1142
15. Bacher U., Hochhaus A., Berger U., et al. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia 19 (2005) 460-463
16. Fayad L., Kantarjian H., O'Brien S., et al. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 11 (1997) 767-771
17. Andersen M.K., Pedersen-Bjergaard J., Kjeldsen L., Dufva I.H., and Brondum-Nielsen K. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 16 (2002) 1390-1393
18. Bumm T., Muller C., Al-Ali H.K., et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101 (2003) 1941-1949
19. Chee Y.L., Vickers M.A., Stevenson D., Holyoake T.L., and Culligan D.J. Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones. Leukemia 17 (2003) 634-635
20. O'Dwyer M.E., Gatter K.M., Loriaux M., et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 17 (2003) 481-487
21. Patchenko P., Klepfish A., Trakhtenbrot L., Rothman R., and Rachmilewitz E.A. Reciprocal relationship between a Ph-negative clone with trisomy 8 associated with severe myelodysplasia and a Ph-positive clone following imatinib treatment in a patient with accelerated-phase chronic myelogenous leukemia (CML). Am J Hematol 77 (2004) 420
22. Perel J.M., McCarthy C., Walker O., Irving I., Williams B., and Kennedy G.A. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica 90 Suppl. (2005) ECR25
23. Jin Huh H., Won Huh J., Myong Seong C., Lee M., and Soon Chung W. Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome. Am J Hematol 74 (2003) 218-220
24. Cherrier-De Wilde S., Rack K., Vannuffel P., Delannoy A., and Hagemeijer A. Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission. Leukemia 17 (2003) 2046-2048